A biotech company tries to retrofit a lung drug to prevent Covid-19’s after effects
As the world scrambles to find antiviral treatments and vaccines for the novel coronavirus, some scientists are looking ahead to a problem on the horizon: Many Covid-19 survivors will have long-term lung injuries, and medicine has little to offer them.
There’s only scant data on how many patients who recover from Covid-19 are left with long-term fibrosis, or scarring of the lung. But studies on SARS and MERS, relatives of the novel coronavirus, suggest about 30% of patients had signs of fibrotic lung disease months after recovery. And, considering the novel coronavirus has already infected more than 5 million people worldwide, debilitating lung problems could become a global scourge.
